Jump to content

Neurolixis: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Tag: Reverted
m Reverted edits by 83.255.8.190 (talk): not providing a reliable source (WP:CITE, WP:RS) (HG) (3.4.10)
Line 24: Line 24:


'''Neurolixis''' is a biopharmaceutical company focused on novel drugs for the treatment of human [[central nervous system]] diseases.
'''Neurolixis''' is a biopharmaceutical company focused on novel drugs for the treatment of human [[central nervous system]] diseases.
Purpose of the Company’s operation is profit. The Company is not what it claims to be. It is Company having only one employee, there is no such thing as a "Headquarters". The Business idea is to get donations from charity organizations supporting research on Parkinson’s disease.


Neurolixis Inc. was founded in 2011 by Mark A. Varney, PhD, and Adrian Newman-Tancredi, PhD, DSc. (Chief Executive Officer <ref>https://www.linkedin.com/in/adriannewmantancredi/ {{Self-published source|date=June 2022}}</ref>). The company's therapeutic focus is on CNS disorders including Parkinson's disease, neurological orphan disorders, depression and cognitive deficits.<ref>{{cite web |url=http://neurolixis.com/home.html |title=neurolixis.com |publisher=neurolixis.com |accessdate=2014-05-17 |url-status=dead |archiveurl=https://web.archive.org/web/20140517172109/http://neurolixis.com/home.html |archivedate=2014-05-17 }}</ref> The company has offices in USA and in France.<ref>{{Cite web |url=http://www.castres-mazamet.com/html/poles-sud/50/#7/z |title=Pôles Sud n°50 - le magazine de l'agglomération de Castres-Mazamet |access-date=2015-06-25 |archive-url=https://web.archive.org/web/20150626143506/http://www.castres-mazamet.com/html/poles-sud/50/#7/z |archive-date=2015-06-26 |url-status=dead }}</ref>
Neurolixis Inc. was founded in 2011 by Mark A. Varney, PhD, and Adrian Newman-Tancredi, PhD, DSc. (Chief Executive Officer <ref>https://www.linkedin.com/in/adriannewmantancredi/ {{Self-published source|date=June 2022}}</ref>). The company's therapeutic focus is on CNS disorders including Parkinson's disease, neurological orphan disorders, depression and cognitive deficits.<ref>{{cite web |url=http://neurolixis.com/home.html |title=neurolixis.com |publisher=neurolixis.com |accessdate=2014-05-17 |url-status=dead |archiveurl=https://web.archive.org/web/20140517172109/http://neurolixis.com/home.html |archivedate=2014-05-17 }}</ref> The company has offices in USA and in France.<ref>{{Cite web |url=http://www.castres-mazamet.com/html/poles-sud/50/#7/z |title=Pôles Sud n°50 - le magazine de l'agglomération de Castres-Mazamet |access-date=2015-06-25 |archive-url=https://web.archive.org/web/20150626143506/http://www.castres-mazamet.com/html/poles-sud/50/#7/z |archive-date=2015-06-26 |url-status=dead }}</ref>

Revision as of 15:59, 28 January 2023

Neurolixis
IndustryBiopharmaceuticals
Founded2011
Headquarters
United States Edit this on Wikidata
Key people
Mark A. Varney, Adrian Newman-Tancredi

Neurolixis is a biopharmaceutical company focused on novel drugs for the treatment of human central nervous system diseases.

Neurolixis Inc. was founded in 2011 by Mark A. Varney, PhD, and Adrian Newman-Tancredi, PhD, DSc. (Chief Executive Officer [1]). The company's therapeutic focus is on CNS disorders including Parkinson's disease, neurological orphan disorders, depression and cognitive deficits.[2] The company has offices in USA and in France.[3]

In September 2013, Neurolixis in-licensed two clinical-phase drugs from Pierre Fabre Laboratories, a French pharmaceutical company. The drugs (befiradol and F-15599) are targeted to the treatment of dyskinesia in Parkinson's disease and to breathing deficits in Rett syndrome, respectively.[4] In addition, Neurolixis is developing its own novel chemical entities (NCEs).

Neurolixis has been awarded a series of research grants by the Michael J. Fox Foundation and by Parkinson's UK. Neurolixis undertook research examining the effects of novel, highly selective and efficacious serotonergic drugs targeting 5-HT1A receptors in brain regions relevant to therapeutic properties in Parkinson's disease.[5] The Michael J. Fox Foundation subsequently announced that it was supporting proof-of-principle studies on befiradol (also known as NLX-112) in models of Parkinson's disease[6] and showcased Neurolixis in its Partnering Program.[7] In January 2018, the British charity Parkinson's UK announced that it had awarded Neurolixis a grant to advance development of befiradol up to clinical phase in Parkinson's disease patients.[8] In March 2019, Neurolixis announced that the US Food and Drug Administration (FDA) gave a positive response to Neurolixis' Investigational New Drug (IND) application for befiradol to be tested in a Phase 2 clinical study in Parkinson's disease patients with troublesome Levodopa-induced dyskinesia.[9] Studies published in 2020 using non-human primate models of Parkinson's disease, (MPTP-treated marmosets and MPTP-treated macaques), found that befiradol potently reduced Levodopa-induced dyskinesia at oral doses as low as 0.1 to 0.4 mg/kg.[10][11]

On 22 November 2020, The Sunday Times reported that the two charities, Parkinson's UK and Michael J. Fox Foundation, were jointly investing $2 million to support a clinical trial on befiradol in Parkinson's disease patients with troublesome Levodopa-induced dyskinesia, a potentially "life changing" drug.[12] On 23 November 2020, Parkinson's UK and Michael J. Fox Foundation, confirmed their funding in an official announcement.[13]

F-15599 (also known as NLX-101) was awarded Orphan Drug Status by the United States Food and Drug Administration (FDA) in October 2013[14] and Orphan Medicinal Product designation by the European Medicines Agency in March 2014.[15] In collaboration with researchers at the University of Bristol, Neurolixis has been awarded a grant by the International Rett Syndrome Foundation to study F-15599 in animal models of Rett syndrome.[16] In June 2015, Neurolixis was awarded a grant by the Rett Syndrome Research Trust to advance F-15599 to clinical development.[17] Subsequent studies on F-15599 investigated its functional selectivity (also referred to as 'biased agonism') at cortical serotonin 5-HT1A receptors using brain imaging techniques in rat: functional magnetic resonance imaging[18] and positron emission tomography.[19] The functional selectivity of F-15599 was considered to underlie its rapid-acting antidepressant-like activity in the 'chronic mild stress' (CMS) model of depression. F-15599 reversed CMS-induced anhedonia (measured as a deficit in sucrose solution consumption) after a single day of treatment.[20]

In addition to developing befiradol and F-15599, Neurolixis is also developing its own novel chemical entities (NCEs) in collaboration with a team at Jagiellonian University in Krakow, Poland. Scientists from Neurolixis and Jagiellonian University filed a patent application on the NCEs in 2016,[21] and it issued in the USA under patent number US10562853B2.[22] The NCEs are selective serotonin 5-HT1A receptor agonists that show functional selectivity for either extracellular signal-regulated kinases activation[23] or for beta arrestin activation.[24] It has been suggested that such compounds may have utility for treatment of distinct CNS disorders.[25]

References

  1. ^ https://www.linkedin.com/in/adriannewmantancredi/ [self-published source]
  2. ^ "neurolixis.com". neurolixis.com. Archived from the original on 2014-05-17. Retrieved 2014-05-17.
  3. ^ "Pôles Sud n°50 - le magazine de l'agglomération de Castres-Mazamet". Archived from the original on 2015-06-26. Retrieved 2015-06-25.
  4. ^ "NEUROLIXIS ANNOUNCES IN-LICENSING OF TWO CLINICAL COMPOUNDS FROM PIERRE FABRE MEDICAMENT" (PDF). neurolixis.com. September 23, 2013. Retrieved 2019-06-05.
  5. ^ "Parkinson's Disease Grants funded by the Michael J. Fox Foundation | The Michael J. Fox Foundation". Michaeljfox.org. 2012-10-26. Retrieved 2014-05-17.
  6. ^ "Predicting the Efficacious Dose of the Selective 5-HT1A Agonist NLX-112". The Michael J. Fox Foundation for Parkinson's Research - Parkinson's Disease.
  7. ^ "Partnering Program of the Michael J. Fox Foundation for Parkinson?s Research | Parkinson's Disease Information". Archived from the original on 2015-06-26. Retrieved 2015-06-25.
  8. ^ "Investing in a new treatment for dyskinesia - Parkinson's UK". www.parkinsons.org.uk.
  9. ^ Inc, Neurolixis. "FDA Approves Neurolixis IND Application for a Clinical Trial with NLX-112 in Parkinson's Disease". PRLog. {{cite web}}: |last= has generic name (help)
  10. ^ Depoortere, R.; Johnston, T.H.; Fox, S.H.; Brotchie, J.M.; Newman-Tancredi, A. (September 2020). "The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques". Parkinsonism & Related Disorders. 78: 151–157. doi:10.1016/j.parkreldis.2020.08.009. PMID 32846366. S2CID 221343904.
  11. ^ Fisher, Ria; Hikima, Atsuko; Morris, Rebecca; Jackson, Michael J.; Rose, Sarah; Varney, Mark A.; Depoortere, Ronan; Newman-Tancredi, Adrian (May 2020). "The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets". Neuropharmacology. 167: 107997. doi:10.1016/j.neuropharm.2020.107997. PMC 7103782. PMID 32057799.
  12. ^ "'Life-changing' drug to calm Parkinson's twitches set for human trials".
  13. ^ "Global charities join forces to drive forward new drug for Parkinson's".
  14. ^ "Search Orphan Drug Designations and Approvals". Accessdata.fda.gov. 2013-10-25. Retrieved 2014-05-17.
  15. ^ "Community register of orphan medicinal products". Ec.europa.eu. Retrieved 2014-05-17.
  16. ^ Bristol, University of. "April: Rett syndrome research - News - University of Bristol". www.bristol.ac.uk.
  17. ^ "RSRT Awards $530,000 to Neurolixis for Clinical Development of NLX-101". 24 June 2015.
  18. ^ Vidal, Benjamin; Fieux, Sylvain; Redouté, Jérôme; Villien, Marjorie; Bonnefoi, Frédéric; Le Bars, Didier; Newman-Tancredi, Adrian; Costes, Nicolas; Zimmer, Luc (October 2018). "In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging". Neuropsychopharmacology. 43 (11): 2310–2319. doi:10.1038/s41386-018-0145-2. PMC 6135772. PMID 30030540.
  19. ^ Levigoureux, Elise; Vidal, Benjamin; Fieux, Sylvain; Bouillot, Caroline; Emery, Stéphane; Newman-Tancredi, Adrian; Zimmer, Luc (17 July 2019). "Serotonin 5-HT 1A Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [ 18 F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats". ACS Chemical Neuroscience. 10 (7): 3108–3119. doi:10.1021/acschemneuro.8b00584. PMID 30576601. S2CID 58663413.
  20. ^ Depoortère, Ronan; Papp, Mariusz; Gruca, Piotr; Lason-Tyburkiewicz, Magdalena; Niemczyk, Monika; Varney, Mark A; Newman-Tancredi, Adrian (November 2019). "Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model". Journal of Psychopharmacology. 33 (11): 1456–1466. doi:10.1177/0269881119860666. PMID 31290370. S2CID 195871156.
  21. ^ "Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors". 23 June 2017.
  22. ^ "Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors".
  23. ^ Sniecikowska, Joanna; Gluch-Lutwin, Monika; Bucki, Adam; Więckowska, Anna; Siwek, Agata; Jastrzebska-Wiesek, Magdalena; Partyka, Anna; Wilczyńska, Daria; Pytka, Karolina; Pociecha, Krzysztof; Cios, Agnieszka; Wyska, Elżbieta; Wesołowska, Anna; Pawłowski, Maciej; Varney, Mark A.; Newman-Tancredi, Adrian; Kolaczkowski, Marcin (14 March 2019). "Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT 1A Receptor-Biased Agonists with Robust Antidepressant-like Activity". Journal of Medicinal Chemistry. 62 (5): 2750–2771. doi:10.1021/acs.jmedchem.9b00062. PMID 30721053.
  24. ^ Sniecikowska, Joanna; Gluch-Lutwin, Monika; Bucki, Adam; Więckowska, Anna; Siwek, Agata; Jastrzebska-Wiesek, Magdalena; Partyka, Anna; Wilczyńska, Daria; Pytka, Karolina; Latacz, Gniewomir; Przejczowska-Pomierny, Katarzyna; Wyska, Elżbieta; Wesołowska, Anna; Pawłowski, Maciej; Newman-Tancredi, Adrian; Kolaczkowski, Marcin (8 October 2020). "Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT 1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile". Journal of Medicinal Chemistry. 63 (19): 10946–10971. doi:10.1021/acs.jmedchem.0c00814. PMC 7586344. PMID 32883072.
  25. ^ Sniecikowska, Joanna; Newman-Tancredi, Adrian; Kolaczkowski, Marcin (10 December 2019). "From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery". Current Topics in Medicinal Chemistry. 19 (26): 2393–2420. doi:10.2174/1568026619666190911122040. PMID 31544717. S2CID 202731822.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Neurolixis&oldid=1136069737"